IBRX is trading at $7.80, up 4.14%.
🟢 Immunitybio Inc is trading 4.14% up
Immunitybio Inc
Related News
IBRX
ImmunityBio Reports 71% Complete Response Rate in Bladder Cancer Trial
IBRX
🔴 Immunitybio is trading 5% down today amid biotech sector weakness
IBRX
🟢 Immunitybio is trading 5.65% up today after FDA expanded ANKTIVA approval for bladder cancer treatment
IBRX
IBRX Receives Expanded FDA Approval for ANKTIVA in Bladder Cancer Treatment
IBRX